HIV-VAC To Investigate IMNR's HIV Vaccine Setback
TORONTO, ONTARIO (June 3) BUSINESS WIRE -June 3, 1999--HIV-VAC, Inc,
(OTC BB:HIVC) announced today that Dr. Gordon Skinner, MD (Hons), DSc,
FRCOG, FRCPath, the developer of HIV-VAC's HIV vaccine has expressed
interest in Immune Response Corp's (NASDAQ:IMNR) Remune HIV vaccine
tests that have ended due to their minimal effect when added to
conventional anti-HIV "cocktail" therapies.
"I am very interested in examining Immune Response Corp.'s conclusion
of their Phase III HIV vaccine trials. This was done on the
recommendation of an Independent Data Safety Monitoring Board (DSMB),"
Dr. Skinner said. "We will be requesting detailed, unprocessed
information on these trials from the DSMB to help us further our
development of our HIV-VAC vaccine which will begin clinical trials
within six to nine months."
HIV-VAC's HIV vaccine was developed by Dr. Skinner at the University
of Birmingham, United Kingdom. It has been under development for the
last 10 years. Toxicity trials are almost completed.
Dr. Skinner added, "The HIV-VAC vaccine is expected to prevent the
disease, and also may prevent the onset of AIDS in HIV-positive
patients. Many scientists have been working on a vaccine for AIDS over
the last 10 years. We have developed a new approach to the AIDS problem
through the creation of an intracellular vaccine based on technology
proven in clinical trials with herpes genitalis and pre-clinical
research into cytomegalovirus and equine herpes vaccines."
The HIV-VAC patented intracellular vaccine approach includes gp120/160
and uses core proteins p55, p24, p17 and others. The multi-protein
approach used by HIV-VAC covers the whole spectrum of HIV virus
proteins and is believed to offer a rational approach both as a vaccine
and for therapeutic purposes. Because the HIV-VAC vaccine proteins are
harvested from virus particles and from intracellular virus-coded
proteins, the entire spectrum of virus proteins is available for
presentation to the immune system.
The United Nations estimates that there are currently 30.6 million
people infected worldwide with the AIDS virus. The disease is spreading
at a rate of 10,000 people each day. It is estimated that the number of
people infected with the AIDS virus by the end of the year 2000 will be
55 million.
The statements contained in this release which are not historical
facts contain forward-looking information with respect to plans,
projections or future performance of the company; the occurrence of
which involves certain risks and uncertainties that could cause the
company's actual results to differ materially from expected results.
Such risks include the timing of implementation and the scope and
success of the program described here.
-0- mj/ny* nmb
CONTACT: HIV-VAC, Toronto
K. Jelsing, Investor Relations
877/778-7731
or
For Live Interview:
www.wallstreetinterview.com
KEYWORD: INTERNATIONAL CANADA
INDUSTRY KEYWORD: MEDICINE Today's News On The Net - Business Wire's
full file on the Internet |
